RxDoctor Payments Data

Gregorio Jimenez

Physician Assistant · Schertz, TXNPI 1447734629

Payments from drug & device makers

$1,916in general payments, 2019–2025

Across 54 payments — averaging $35.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$547
  • Novo Nordisk$436
  • Lilly USA, LLC$339
  • AstraZeneca$254
  • Merck$146
  • Amgen$88
  • plus $107 from 4 others

What the payments were for

  • Food & beverage$1,916100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,916 in reported general payments places this provider in the 75th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas

Medicare billing

Part B allowed, 2024
$26,694
Medicare patients
171
Services billed
496

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide83$119,248
JardianceEmpagliflozin67$96,405
TrulicityDulaglutide56$85,097
FarxigaDapagliflozin Propanediol39$58,882
EliquisApixaban22$32,377
MounjaroTirzepatide20$30,436
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$27,405
Breztri AerosphereBudesonide/Glycopyr/Formoterol33$23,667
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog28$19,399
MyrbetriqMirabegron17$19,175
BelsomraSuvorexant21$9,408
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr14$8,643
SymbicortBudesonide/Formoterol Fumarate18$4,962
VascepaIcosapent Ethyl11$3,944
Albuterol Sulfate HfaAlbuterol Sulfate184$3,911

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$436$119,24883 claims
Lilly USA, LLCTrulicity, Mounjaro$339$115,53376 claims
Boehringer IngelheimJardiance$20$96,40567 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$254$87,51190 claims
MerckBelsomra$146$9,40821 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in Schertz

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →